IOncology

From the first glimmer of insight in 1941, when Professor Charles Huggins discovered the hormone dependence of prostate cancer, to today’s flourishing era of precision oncology, the field of genitourinary cancers has traveled an extraordinary path—from silence and therapeutic limitation to an age of precision-driven breakthroughs. As both a participant in and witness to this journey, I feel deeply honored and profoundly inspired.

From the moment Charles Huggins first demonstrated the hormone dependence of prostate cancer in 1941, genitourinary oncology has evolved from an era of limited treatment possibilities into one defined by precision medicine and therapeutic innovation.

The 4th Urologic Oncology Clinical Research Conference brought together leading experts, investigators, and innovators to review the latest progress in genitourinary oncology research in China. Alongside academic forums and international expert discussions, the meeting also released the 2025 Annual Report on Chinese Genitourinary Oncology Clinical Research, offering a comprehensive overview of the field’s recent development.

In recent years, both renal cell carcinoma and upper tract urothelial carcinoma (UTUC) have entered an era of rapid transformation, driven by advances in precision oncology, organ-preserving strategies, and systemic combination therapies.

At the 4th Urologic Oncology Clinical Research Conference, UroStream invited Professor Xinan Sheng from Peking University Cancer Hospital to discuss the evolving landscape of urologic oncology, the core principles behind…

As one of the most common malignancies affecting men worldwide, prostate cancer requires continuously evolving diagnostic and therapeutic strategies. With rapid advances in precision medicine and the growing body of high-quality clinical evidence generated from Chinese patient populations, the 2026 CSCO Guidelines for Prostate Cancer introduce major updates aimed at better addressing the biological characteristics and clinical needs of patients in China.

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Professor Xieqiao Yan from Peking University Cancer Hospital delivered a comprehensive presentation on the latest advances in kidney cancer therapy. His report focused on emerging clinical evidence surrounding the HIF-2α inhibitor belzutifan, particularly its evolving role in advanced clear cell renal cell carcinoma (ccRCC) after PD-1–based therapy, as well as in the postoperative adjuvant setting. The findings offer important new insights for clinical decision-making in the post-PD-1 era.